AUTO-GENERATED · CITATION-ONLY · 2026-07-09
$TARS — convergence catalyst
Convergence score: 33.0 ·
Signals fired: 12
(deepvalue;squeeze;finra_short;short;xbrl_ni;biotech;gamma;auto_macro_ace_mag;auto_macro_adp_payrolls;auto_macro_bls_employment;auto_macro_boc_yields;auto_macro_edgar_fts) ·
Conviction: ELEVATED
Auto-generated from public filings. This is not financial advice.
Confirm independently before trading. Catalyst Edge holds positions consistent
with our published signals — see
trust report.
Citation block only. Automated narrative unavailable this cycle (reason: no_citations_in_summary).
Sources
- [1] ALPHAVANTAGE · Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101 · 2026-07-08T19:40:00
- [2] ALPHAVANTAGE · (TARS) and the Role of Price-Sensitive Allocations · 2026-06-29T05:08:00
- [3] ALPHAVANTAGE · Tarsus (NASDAQ: TARS) acquires iRenix, adds late-stage IRX-101 eye asset · 2026-07-08T20:40:00
- [4] ALPHAVANTAGE · Did Copay Allegations and New Director Equity Awards Just Shift Tarsus Pharmaceuticals' (TARS) Investment Narrative? · 2026-07-03T20:10:59
- [5] ALPHAVANTAGE · Tarsus Pharmaceuticals Faces Medicare Copay Allegations From Culper Research; Shares Fall · 2026-07-01T23:09:52
- [6] Catalyst Edge convergence detector · Convergence score 33.0, 12 signals fired: deepvalue, squeeze, finra_short, short, xbrl_ni, biotech, gamma, auto_macro_ace_mag, auto_macro_adp_payrolls, auto_macro_bls_employment, auto_macro_boc_yields, auto_macro_edgar_fts · 2026-07-09T20:37:19
Underlying signal breakdown
| Field | Value |
| convergence_score | 33.0 |
| conviction_level | ELEVATED |
| signal_count | 12 |
| sector | biotech |
| price | |
⚠️ Position disclosure: Catalyst Edge holds
a small live equity position in tickers that pass the convergence + scoop
publish gate. Real-time P/L, fills, and the running ledger are public at
/trust/. Specific entry
on
TARS: see
/scoreboard/
for outcome tracking. Bloomberg legally cannot disclose this; we do.